All In Biotech

Drug Trial Radar · NCT02570308

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Last checked: Nov 20, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

146

Actual

Start

Feb 29, 2016

Primary completion

Mar 20, 2020

Study completion Oct 17, 2022

Sponsor

Lead sponsor
Immunocore LtdIndustry
Sponsor type
Industry
First posted
Oct 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM). According to this regimen, all participants in the trial received 2 weekly doses of IMCgp100 at a dose level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose escalation commenced at the third weekly dose at C1D15. The Phase I testing of the intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter.

Conditions

  • Uveal Melanoma

Interventions

  • IMCgp100Drug

    Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1Time frame: Up to 49 months
  2. Objective Response Rate in Phase 2Time frame: Up to 38 months

Locations

26 sites in 5 countries. Site status is shown where the registry gives one.

  • University California, San Diego Moores Cancer Center

    La Jolla, California

  • The Angeles Clinic and Research Institute - W LA Office

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • University of Colorado Denver Anschutz Medical Campus

    Aurora, Colorado

  • Georgetown University - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • University of Miami Hospital Clinics/Sylvester Comprehensive Cancer Center

    Miami, Florida

  • H. Lee Moffitt Cancer Center and Research Institute, Inc

    Tampa, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Washington University, School of Medicine

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University Medical Center - The New York Presbyterian Hospital

    New York, New York

  • Memorial Sloan Kettering Hospital

    New York, New York

  • Dean A. Mcgee Eye Institute

    Oklahoma City, Oklahoma

  • Providence Portland Medical Center

    Portland, Oregon

  • Thomas Jefferson University Medical Oncology Clinic

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor Scott & White Health

    Temple, Texas

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

    Berlin, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Hospital General Universitario de Valencia

    Valencia, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, Spain

  • The Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, Merseyside, United Kingdom

  • Mount Vernon Cancer Centre

    Northwood, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.